Proximity Ligation Assays Show Potential to Detect Altered EGFR Signaling, Predict Drug Response | GenomeWeb

NEW YORK (GenomeWeb) – A study by a team from the Moffitt Cancer Centerhas demonstrated that proximity ligation assays, which detect aberrant gene signaling, can predict response to EGFR-inhibiting drugs.

The study results, published this week in Science Signaling, suggest that this approach could potentially complement mutation-based molecular diagnostics currently used to guide treatment with EGFR inhibitors, by detecting targetable aberrant EGFR signaling even in patients who have normal genotypes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.